Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The association between the pathogenesis and natural course of nonalcoholic fatty liver disease (NAFLD) and skeletal muscle dysfunction is increasingly recognized. These obesity-associated disorders originate primarily from sustained caloric excess, gradually disrupting cellular and molecular mechanisms of the adipose-muscle-liver axis resulting in end-stage tissue injury exemplified by cirrhosis and sarcopenia. These major clinical phenotypes develop through complex organ-tissue interactions from the earliest stages of NAFLD. While the role of adipose tissue expansion and remodeling is well established in the development of NAFLD, less is known about the specific interplay between skeletal muscle and the liver in this process. Here, the relationship between skeletal muscle and liver in various stages of NAFLD progression is reviewed. Current knowledge of the pathophysiology is summarized with the goal of better understanding the natural history, risk stratification, and management of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 1×
“A commonly used parameter is appendicular skeletal muscle mass (also referred to as ASM) adjusted for height to yield appendicular skeletal muscle index (also referred to as SMI).(28) Skeletal muscle cross-sectional imaging with magnetic resonance (MR) or computed tomography (CT) has become the gold standard, focusing…”
MethodCruz-Jentoft, A. J., & Sayer, A. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31138-9 · Cited by 3,905
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Muscles, exercise and obesity: skeletal muscle as a secretory organ
Pedersen, B. K., & Febbraio, M. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.49 · Cited by 2,909 · cited 3×
“Myostatin is a TGF-b superfamily member and a negative regulator of skeletal muscle mass.(63) Myostatin interferes with mTOR signaling and activates skeletal muscle proteolysis through autophagy and the ubiquitin-proteasome pathway.”
BackgroundSarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 1×
“As the name implies, sarcopenia is a condition with diminished skeletal muscle mass, first associated with older age.(23) Today, sarcopenia has a complex meaning as a progressive and generalized disorder seen in various chronic illnesses.”
BackgroundNon-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder of our time, affecting more than one billion people worldwide and with an estimated 30% prevalence in the adult US population, representing a significant global healthcare burden.(1,2) NAFLD is a manifestation of metabolic syndrome i…”
BackgroundAdipose Tissue as an Endocrine Organ
Ahima, R. S., & Flier, J. S. (2000) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00301-5 · Cited by 1,608
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392 · cited 1×
“NAFLD may progress to cirrhosis, and it confers an increased risk of hepatocellular carcinoma.(4,5) However, prediction of clinical outcomes in NAFLD has proven challenging as environmental and genetic drivers of its progression are not fully identified.”
Background
Cited by
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Nachit, M., Kwanten, W. J., Thissen, J.-P., Op De Beeck, B., Van Gaal, L., Vonghia, L., Verrijken, A., Driessen, A., Horsmans, Y., Francque, S., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.037 · Cited by 114
Metadata
- Authors
- Altajar, S., & Baffy, G.
- Venue
- Journal of Clinical and Translational Hepatology
- Publisher
- Xia & He Publishing
- Published
- 2020-10-15
- Volume
- 8
- Issue
- 4
- Pages
- 1-10
- ISSN
- 2225-0719 (ISSN-L)
- 2310-8819
- OpenAlex
- W3092691115
- Cited by
- 72
- References
- 37
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.14218/jcth.2020.00065
- The paper
- Altajar, S., & Baffy, G. (2020). Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology. https://doi.org/10.14218/jcth.2020.00065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.